class,text
N,'Neither patients nor researchers were blinded to treatment'' Different dosage schedules make blinding impossible Potential knowledge of treatment may have influenced the primary outcome of MBL which was measured by PBAC
P,"""... the vaccination rates were estimated through administrative data."""
Q,"""180 patients were included in the study and randomly allocated to group A or B."""
N,"""A brightly coloured sticker was applied to the charts of the entire study population as a reminder to the health-care team that the study was under way and that they were expected to promote the flu vaccine.""; ""The patients would be 
told, whether by telephone or in the office, that the vaccine was available, and 
that they would be given a shot if they wished."""
P,"""A central research pharmacy over-capsulated 300 mg gabapentin and placebo capsules to appear identical"". Participants ""visually shielded from the image screen"" during injections"", had no further contact with physician"
Q,"""Active (mefenamic acid 500 mg) and placebo tablets, which were identical in appearance, were packaged in coded bottles, randomisation being provided by the manufacturer."""
N,"""after the initial treatment session, research technicians were not blind to group status. Research Technicians were not aware of the patients’ group status when conducting interviews and administering measures during the initial baseline assessment and treatment session."""
P,"""all capsules were identical in taste, color, size, and shape"""
Q,"""All patients received an appropriate combination of active and placebo tablets to achieve the required dosing and maintain the study blind - implies active and placebo were indistinguishable"""
P,"""all study medication was matched with placebo to maintain the double-blind nature of the study"""
P,"""Although contamination of the control group is sometimes a concern with such a design, it was not an issue here for two reasons: first, the financial intervention involved full Medicare reimbursement to physicians for preventive-care and health promotion packages only for those patients randomised to the intervention group; and second, the office system intervention was in effect only for patients receiving the intervention group. The control group was not identified to the practice, there was no prompting, no form, and no special preventive visit for the control-group patients""; ""Patients were informed of their random assignment only after they came into the practice for the interview"""
P,"""amoxicillin-placebo"" ""double-blind trial"""
P,"""blinded study"" ""placebo capsules"""
Q,"""Blinding, in the sense of blinding the investigators, was not necessary because the judgement of whether a preventive activity (including the administration of influenza vaccine) had been performed was made by searching the practice's electronic clinical record automatically""; ""Vaccinations were recorded by the doctors in their clinical record system's immunization module which used coded data entry to make the entries consistent and therefore machine-searchable. If our search found a record of influenza vaccine being given between 9th March (the start of our trial) and the 
end of June (the end of the useful immunization season), this was counted as 
influenza immunisation having been performed"""
P,"""blindly assigned (1:2 ratio) using computer generated random numbers either to integrated care (IC) or to usual care (UC)."""
Q,"""Both the patient and the attending physician were blinded as to the medication assignment""; no additional details provided with respect to outcome assessment"
P,"""capsules that were identical in appearance"""
P,"""capsules that were identical in appearance"""
P,"""double blind and used a single placebo technique"""
P,"""double blind, double dummy design"""
P,"""double blind, double dummy"""
P,"""double blind,double dummy"""
P,"""double blind? Using placebo of the same size and appearance as conventional metronidazole and clarithromycin tablets"""
Q,"""Double blind"""
P,"""double blind"" ""antibiotic matching placebo"""
P,"""double blind"" ""placebo treatment"""
P,"""double blind"" placebo"
P,"""double blind"" placebo"
P,"""double blind"", The medicine, starch or placebo (gastropine) was packed in gelatin capsules of similar appearance. The investigators did not know what medicines were given to patients, and the patients did not know what medicines they had taken"""
P,"""double dummy"""
P,"""double-blind"" ""identically appearing placebo"""
P,"""Drugs and placebos in exactly identical covering with codes only known to the researchers were given to the study samples."""
P,"""drugs placed in identical capsules"", ""matching placebo of nortriptyline"" to blind different dosing schedules"
P,"""endoscopic examinations were ultimately judged by an experienced endoscopist who was also not informed of the treatment"""
P,"""Endoscopies were performed by one of the authors, who was blinded to the clinical data, bacteriological findings and treatment regimen"""
P,"""endoscopy was performed at 3 month intervals by a gastroenterologist who was kept uninformed of the details of the patients' past medical histories"""
P,"""Gel was given prior to the investigation by a different operator from those who carried out hysteroscopy, and the patient, hysteroscopist and other staC were unaware of which gel had been used."""
P,"""identical appearing blue and grey capsules .... in accord with a double-dummy design"""
P,"""identical appearing placebos"""
P,"""identical capsules"""
P,"""identical capsules"""
P,"""identical capsules"""
P,"""identical placebo capsules"""
P,"""identical tablets/capsules containing active drug or placebo"""
P,"""Identical-appearing capsules containing placebo were used to blind the patients"""
P,"""identical-appearing capsules"""
P,"""identical, coded medication bottles containing identical tablets of gabapentin or placebo"""
P,"""identically appearing capsules"""
P,"""identically appearing capsules"""
P,"""identically appearing capsules"""
P,"""identically appearing placebo"""
P,"""In view of the double blind...both the active and the placebo infusions were coloured yellow..."""
P,"""Interviewers evaluating outcomes were blinded to the intervention group of participants and general practitioners at all times, and participants were unaware of the group allocation of their general practitioner."""
P,"""interviews carried out by a research assistant blinded to group assignment"""
P,"""investigator blinded clinical trial"""
P,"""investigator blinded"""
P,"""matched placebo"""
P,"""matching placebo"""
P,"""matching placebos were supplied to maintain the double-blind nature of the study"""
Q,"""Neither operating physician nor patient was are of which study antibiotic was used""; however, no details on outcome assessors were provided"
P,"""Nurses who undertook the vaccination clinics were unaware of the household allocation to control or intervention group."""
N,"""open study"""
P,"""Patients and investigators (or other personnel performing patient evaluations) were not aware of which regimen was being administered"""
P,"""Patients and their physicians were aware of the treatment assignment, but endoscopists and pathologists were not"""
P,"""Patients, researchers, and others involved in patient care were blind to study group; only acupuncturists and the designated research assistant were aware of which patients received true and which received placebo treatment"""
P,"""Patients, their gynaecologists, all investigators and evaluators were blinded to the random allocation throughout the study"""
P,"""Physicians and facilitators were blinded to the actual manoeuvres that would be included in the preventive performance index."""
P,"""placebo capsules were identical in appearance and taste"""
Q,"""Randomization was performed using a predetermined randomization code in a double blind fashion."""
P,"""results were not shared with the endoscopist"""
P,"""single blind"""
Q,"""single-blind"", but does not state if it was participants or researchers blinded; data entered on computer clinical tracking program"
P,"""staff performing the endoscopic and bacteriologic assessments were unaware of the drugs the patient had been taking"""
P,"""supplied in identical capsules in blinded fashion"". ""All participants were supplied with an equal number of capsules""."
P,"""The attending doctor, nursing staC and the women were all blinded to the identity of the medication used."""
P,"""The chart auditors were blinded as to the status of the practices and assessment of outcomes."""
P,"""The code was not broken until the woman had been classified as morbid or no-morbid and had been examined 6 weeks after surgery"""
P,"""the endoscopist was blinded to the treatment status of the patient"""
P,"""The investigator and staD were unaware of the antibiotic assignment"""
P,"""the investigator in charge of follow-up was"" blinded to the procedure"
P,"""The patients and the physician investigator were blinded to treatment assignment as long as the 24-hour assessment was not completed. The assessment was performed by the investigator and the nurse who administered the injection was not involved in the assessment process of the study."" (p.232)."
Q,"""The patients as well as the medical staC performing the hysteroscopy were unaware which gel had been used."" However the examiner performing the gel-instillation sonography (GIS) was aware of which gel had been used. Although the relevant intervention was blinded there is a high risk that the blinding could be broken, although the likely impact of this on the results is unclear."
P,"""The randomization code was not broken until the last woman attended the clinic"""
P,"""The single acupuncturist was trained to perform the same procedures at each consultation and was instructed not to discuss any aspect of the treatment procedures with the participants, to ensure participant blinding and consistency of treatment."""
P,"""The study remained blinded until all women were examined at a follow-up clinic visit"""
N,"""The study was not blinded in that physicians could be aware that a patient was a member of a family in the study if the patient mentioned that the family had received a letter."""
P,"""The study was open for participants but blinded for the healthcare workers responsible for caring for the patients."""
P,"""The vaccination data were obtained through prechart and postchart reviews conducted at these sites by trained outside reviewers."""
Q,"""The women were randomised prospectively double blind into two groups."""
N,"""This study was an open-label randomised trial."""
P,"""two experienced endoscopists, who were blind to the clinical data"""
Q,"""Volunteers ... made a follow-up contact to ascertain whether immunization(s) were received."""
Q,"""With placebo blinding"" - probably double-blinded; no additional information on outcome assessor"
Q,"""Women were randomly and double blindly assigned."""
Q,"""Women were randomly and double blindly assigned."""
P,"“10-mg melatonin tablets (Sigma Chemical, Munich, Germany, provided batchby-batch certificates of analysis authenticating the purity of each batch) or a placebo with identical characteristics. The capsules were manufactured in such a way that the placebo and active treatment appeared to be identical.” “Other individuals who were involved in patient care were unaware of the treatment group to which the patients belonged.” “Two independent medical examiners who were blind to the group assignments were trained to administer the pain scales and to conduct the psychological tests.”"
Q,"“A double-blind, randomised, placebo-controlled study carried on 240 high schools female students with dysmenorrhea in Urmia city by dividing into four groups with 60 members.” “They received drug boxes each month, and for all of them, possible drug complications were described and asked them to mention any occurred complications.” Comment: it is unclear whether or not the appearance of the treatment to both groups was the same in all aspects (different form; tablet, capsule)."
Q,"“A randomised, double blind study comparing FEO 1% and 2% with placebo”. Comment: there was no information on either the form of placebo, or the appearance of FEO and placebo. The study may not have accomplished blinding."
P,“Alcohol information was not included in the health packet [received by all participants] to avoid contamination” (p. 69)
P,"“All of the capsules were made by Boo Ali Research Center of Qom city and were completely similar in shape. In regarding the blinding process, the researchers and the participants were uninformed of allocating manner of each group and a third one that did not involve in analysing and interpreting”."
N,"“Blinding was not feasible, either for participants and GPs, or for outcome assessment and statistical analysis (p. 594)"
N,"“Due to our study design, blinding could not be conducted for the individual study participant and the staff member providing the counselling session” (p. 245)"
N,"“Each medication package was placed on a separate box, coded by letters A and B, and was given to each participant.” Comment: it is unclear whether or not the medication appearance in both groups was the same in all aspects, and also whether there was a difference of administrator"
P,"“Fenugreek seed's capsule content of 900 mg seed powder prescribed 3 times a day and 2- 3 capsules duration first three days of menstrual period and for persons in control group prescribed placebo (similar capsule with same recipe content starch) in two cycles.” “The capsules were similar with respect to shape, colour, and packaging.”"
N,"“Given the nature of the intervention, study participants and site staff could not be masked to treatment allocation” (p. 447)"
N,"“Group allocation was not blinded to the participant, clinicians performing interventions or the researchers conducting follow-up interviews” (p. 123)"
P,"“In a double-blind, randomised, placebo controlled trial, 100 students were randomly assigned to receive valerian (n=49) or placebo (n=51).” “The present study was a double-blind, randomised clinical trial.” “The participants and the researchers were blind as to who received valerian.” “The valerian capsules contained 255 mg powder of valerian root, whereas the placebo capsules contained starch. The capsules were similar in shape and packaging.”"
P,"“One of the goals of the trial was to blind subjects assigned to the control groups to minimize possible intervention effects. The subjects in both control groups were told that the trial focused on general health behaviours, including alcohol use” (p. 1228)"
N,"“oral fennel drop”. Comment: blinding was not mentioned. In addition, it is not possible to blind the participant to treatment (liquid forms (drop) versus capsule)."
P,“Participants were not informed of the hypotheses being tested” (p. 1734)
P,“Patients were blinded to the intervention applied” (p. 228)
P,“research assistants who were unaware of the intervention status implemented study procedures”
P,"“The capsules of Rosa damascena extract were produced with the same appearance, colour and odour as Mefenamic acid capsules” “During the study, the participants and the researcher were unaware of the drug”"
P,"“The capsules were identical in shape, package, and colour, and were coded by the pharmacologist. Neither the researcher nor the participants were informed of the type of ingredient in each capsule.”"
Q,"“The ginger and placebo capsules were prepared by a pharmacist. Briefly, fresh ginger root was chopped into small pieces, baked at 60°C for 24 hours, and then ground into powder. Ginger powder was weighed and 500 mg of it was filled in each capsule. Excess powder was wiped oC the capsule surface with a clean dry cloth. Both placebo and ginger capsules were packed in an envelope containing nine capsules.” Comment: it is unclear whether or not capsule appearance in both groups was the same in all aspects (e.g. colour)."
P,“The health screening survey was designed as a general lifestyle questionnaire to increase student acceptance of the research procedures and to minimize the intervention effect of the alcohol questions” (p. 26)
N,“The intervention group received 30 mg fennel capsules each 4 hours (8 am to 12 midnight) from about 3 days before menstruation till end of fiQh day for 3 months. There was no treatment for control group and they did not receive any placebo.” Comment: it was not possible to blind the participant to treatment as the control group did not receive any treatment.
P,"“The phyto-drug, ibuprofen and placebo were manufactured, standardized and packaged at Phyto-drugs Technology Research and Development Laboratory of the Mexican Institute of Social Security.” “All vials of medication (extract, placebo or ibuprofen) were identical and labelled with codes, which were known only to the investigators who manufactured the products.” Comment: participants were likely to be blinded as the interventions were standardised and packaged. All vials of medication were identical and labelled with codes, which were known only to the investigators who manufactured the products."
P,"“The placebo capsules contained toast powder. The capsules were similar in shape, taste and colour but one set contained 500 mg ginger powder per cap sule and the others were placebo capsules. The ginger capsules did not have 
distinguishable smell. The capsules were prepared in the Institute of Medicinal 
Plants and put into coded packages. Capsules and their packages were identical in appearance.” 
“This was a double- blind trial. Both the students and midwife providing care 
were blind to the treatment allocation. For this purpose, coded packages containing ginger and placebo capsules were used. The ginger and placebo capsules were identical in appearance, colour and taste.” 
“Students were asked to indicate a perception of pain intensity (most commonly) along a 10 cm horizontal line. Duration of pain was determined by asking each student to indicate the number of hours she had experienced pain 
during the first three days of the menstrual period.”"
P,"“The shape, size, and colour of the capsule of drugs were similar.” “The study was double-blinded, i.e. the researcher and students did not know which medication was administered.”"
P,"“This was a single-blind trial. The appearances of the experimental and control drug capsules were identical, and no aroma was detected from either”."
P,“trained interviewers who were masked to group assignment and study hypotheses and who had no role in the intervention interviewed them at 6 and 12 months.”
Q,"5 withdrew after randomization (2 in MFA group, 2 in ethamsylate group, 1 in TXA group) and lost to follow-up"
P,"Acupuncture control clearly designed to ensure blinding of participants, though not described as 'blind'"
P,Adequate
P,"Alcohol questions were disguised among questions relating to weight, smoking and exercise. Study was described to patients as being about lifestyles"
P,Alcohol questions were embedded with other health-related questions to minimise the intervention effect of the alcohol questions (p. 2199)
P,"All clinical and research staC were blinded to the allocation of participants, and the allocation schedule was kept in the office of the Chief Research Pharmacist in the host institution."
P,All clinical investigators were blinded to outcome determinations
Q,"All drugs encapsulated, but no mention of equal numbers and regimen or double-dummy method"
P,"All groups received needling treatments, differences unlikely to lead to unblinding in the context"
N,All patients received briefing that the intervention is about alcohol use and driving behaviours
P,All personnel with patient access remained blinded to which machine had been altered and which provided the stimulation.
Q,Although personnel involved in data collection and data analysis blinded it was not reported whether other personnel and participants were blinded.
Q,An oral placebo was used to single-blind participants. However outcome was not determined blind
N,"Article states 'blinding of researchers, clinicians or patients was not possible'."
N,Assessment was done using a 13-item self-reported behaviours questionnaire in the study participants and thereby introduced a possible bias
P,"Authors stated that the other group took ""placebo of identical appearance to the active drug"" and the treatment regimen was also the same for each group"
Q,Automated measurement devices were used but authors don't specifically state that outcome assessors were blinded
P,Blinded data collectors
P,Blinded outcome assessors
P,Blinded outcome assessors
P,Blinded outcome assessors.
P,Blinded outcome assessors.
P,"Blinded participant (though control group felt no electrical stimulation), blinded assessor"
P,Blinded participants and outcome assessors
P,"Blinded. Single physician assessment. ""success of blinding was assessed by the accuracy of the physicians prediction at the end of the study"" (34% correctly identified only)"
Q,Blinding not described
Q,Blinding not possible due to recalls and prompts.
Q,"Blinding not possible, as treating GPs received summary statements about participants as part of intervention."
Q,Blinding not reported
Q,Blinding of assessors was not described Possibly high risk of performance bias for personnel
N,"Blinding of intervention - no Blinding of outcome assessment - yes for chest X-ray, no for use of IPPV"
N,Blinding of intervention - no. Blinding of outcome assessment - not for use of IPPV
P,"Blinding of participant and care provider, but unsure about outcome assessor"
P,"Blinding of participant and care provider, but unsure about outcome assessor"
P,Blinding of participants and personnel
N,Blinding of participants was not mentioned but seemed inadequate or very unlikely since the intervention and control treatment had different routes of administration
Q,"Blinding of participants, study staG or medical staG was not reported."
P,Blinding of postoperative evaluation
N,Blinding of treatment - no. Blinding of outcome assessments - not stated.
N,Blinding was not performed
N,Blinding was not performed
N,Blinding was not performed
N,Blinding was not performed
N,Blinding was not performed
N,Blinding was not performed
N,Blinding was not performed
N,Blinding was not performed
N,Blinding was not performed
N,Blinding was not performed
N,Blinding was not performed
N,Blinding was not performed
N,Blinding was not performed
N,Blinding was not performed
N,Blinding was not performed
N,Blinding was not performed
Q,Blinding was not possible because of the nature of the interventions
Q,Blinding was not possible because of the nature of the interventions and non blinding was not likely to affect the outcomes of interest
Q,Blinding was not possible because of the nature of the interventions and nonblinding was not likely to affect the outcomes of interest
Q,Blinding was not possible because of the nature of the interventions and nonblinding was not likely to affect the outcomes of interest
Q,Blinding was not possible because of the nature of the interventions and nonblinding was not likely to affect the outcomes of interest
Q,Blinding was not possible because of the nature of the interventions and nonblinding was not likely to affect the outcomes of interest
Q,Blinding was not possible because of the nature of the interventions and nonblinding was not likely to affect the outcomes of interest
Q,Blinding was not possible because of the nature of the interventions and nonblinding was not likely to affect the outcomes of interest
Q,Blinding was not possible because of the nature of the interventions and nonblinding was not likely to affect the outcomes of interest
Q,Blinding was not possible because of the nature of the interventions and nonblinding was not likely to affect the outcomes of interest
Q,Blinding was not possible because of the nature of the interventions and nonblinding was not likely to affect the outcomes of interest
Q,Blinding was not possible because of the nature of the interventions and nonblinding was not likely to affect the outcomes of interest
Q,Blinding was not possible because of the nature of the interventions and nonblinding was not likely to affect the outcomes of interest
Q,Blinding was not possible because of the nature of the interventions and nonblinding was not likely to affect the outcomes of interest
Q,Blinding was not possible because of the nature of the interventions and nonblinding was not likely to affect the outcomes of interest
Q,Blinding was not reported
Q,"Blinding was not used due to the nature of the interventions; no information on outcome assessment; however, non-blinding of outcome assessors may not have affected some of the outcome measures as they were objectively assessed."
P,Blinding was performed
P,Both arms receive initial intervention so no differential knowledge of intervention between the groups
P,Both participants and carers blind to treatment allocation
N,Both the investigators and the patients knew whether the patients were assigned to biofeedback or to pills Partial blinding between diazepam and placebo only
P,"Both treatments were clear liquids. Saline (placebo) ""seemed identical to gabapentin"""
P,"Capsules with ""identical shape and colour"""
P,"Comment: Blinding is implied but not explicitly stated. Quote: ""This was a prospective, randomized, double-blind, placebo-controlled clinical trial of the effect of mannitol on systolic BP in multiply injured patients with severe head injuries"". Quote: ""The study solutions were prepared by the pharmacy department and were identified by a code number. An envelope showing the code number identified the contents of that IV bag. If the treating physicians at the receiving trauma center believed it was necessary to know whether the patient had received mannitol or placebo, the envelope could be opened"". Quote: ""At the conclusion of the 2-hour monitoring period, the EM resident and the investigator recording the patient data were asked to provide their guesses as to whether mannitol or placebo had been administered to the patient. For those patients actually given mannitol, the resident correctly picked mannitol in 11 of 13 cases for which a guess was given; and the investigators correctly picked mannitol in 13 of 14 cases. For those patients actually given placebo, the resident correctly picked placebo in 5 of 10 cases for which a guess was given; and the investigators correctly picked placebo for 13 of 16 cases""."
P,Comment: both capsules were identical and packed in similar packages and were only identifiable by a code. Both clinicians and participants were blinded.
P,Comment: both the clinician and participants were blinded.
,Comment: not stated
,"Comment: not stated in study report, but author responded to request for further information by stating the investigators and outcome assessors were blinded."
,"Comment: not stated in study report, but author responded to request for further information by stating the investigators and outcome assessors were blinded."
,"Comment: not stated in study report, but author responded to request for further information by stating the investigators and outcome assessors were blinded."
,"Comment: not stated in study report, but author responded to request for further information by stating the investigators and outcome assessors were blinded."
,"Comment: not stated in study report, but author responded to request for further information by stating the investigators and outcome assessors were blinded. Both Gethin and Jull have reported how it was difficult or impossible to blind outcome assessment due to discolouration of peri-ulcer skin by honey. We have therefore classed all as unclear risk for blinding of outcome assessors."
,"Comment: not stated in study report, but author responded to request for further information by stating the investigators and outcome assessors were blinded. Both Gethin and Jull have reported how it was difficult or impossible to blind outcome assessment due to discolouration of peri-ulcer skin by honey. We have therefore classed all as unclear risk for blinding of outcome assessors"
,"Comment: not stated in study report, but author responded to request for further information by stating the investigators and outcome assessors were blinded. How blinding was achieved was not described in the response."
,Comment: not stated.
,Comment: not stated.
,Comment: not stated.
,Comment: not stated.
,Comment: not stated.
,Comment: not stated. However the difference in interventions means that blinding unlikely.
Q,"Comment: outcome assessors and treating physicians were blinded. Vitamin E and placebo were identical in shape, colour, taste, and smell."
P,"Comment: participants and observers were blinded, and the placebo was identical."
Q,Comment: the study authors did not mention blinding but used a placebo for the comparator.
N,"Comment: the study authors did not mention blinding. In addition, blinding might not be accomplished as the difference of dose (2 tablets versus 1 tablets) and administrator."
,Comment: the study is described by the authors as double blind although quite how blinding was maintained is not reported. Nevertheless we have rated this as low risk for performance bias on the basis of the blinding
Q,Comment: the study states double-blinded.
N,"Comment: the study was not blinded, and there was no placebo intervention."
P,"Comment: triple blinded (patients, clinicians, and statisticians were all blinded). The placebo and cinnamon capsule were completely identical and were manufactured by the same company. They were packed in an identical package and were distinguishable by a code on the packets."
P,"CRC diagnosis and cause of death obtained from public registries. In cases of uncertainty of cause of death, an independent reviewer who was blinded to study group allocation evaluated case records"
P,Daily billing forms were reviewed by trained research assistant.
P,Data extractors abstracted data from primary care practice records and were blinded.
P,Data were obtained from administrative databases and chart review to measure vaccination uptake.
Q,"Described as ""double-blind""; method not described"
Q,"Described as an open-label trial, thus both participants and personnel were aware of the treatment protocols. However, non-blinding of outcome assessors may not have affected some of the outcome measures as they were objectively assessed."
Q,Described as double-blind - no details given
P,"Described as double-blind, and interventions were appropriate"
Q,"Described as double-blind, no further details given."
P,"described as single blind, and interventions appropriate"
P,"Described as single blind, and the interventions were appropriate"
P,"Described as single blind, and the interventions were appropriate"
Q,Described only as double-blinded
Q,Described only as double-blinded
,different interventions at the same site visible
P,Double blind
P,"Double blind, with double-dummy technique"
P,"Double blind. ""Consecutive outpatients were randomly assigned to receive in a double-blind fashion one of the following subcutaneous treatments."" ""All primary and secondary outcomes were evaluated by a central adjudication committee, whose members were not involved in patient recruitment."""
P,Double blind. Women in control group received a placebo.
Q,Double Blind'
P,Double blinded - outcome assessor and the women were blinded
P,Double blinded. “Both the woman and the attending medical staC were unaware of the medication used.”
P,Double blinding (participants and nurses blinded)
P,Double blinding was possible as depot was available in 2% and 10% solutions. No information on test of blinding though.
P,"Double blinding. ""Neither the patient nor the physician were aware of the drug used."""
P,"Double blinding. ""The nurse, the patient and the physician were not aware of the drug used."""
P,Double-blind
P,Double-blind
Q,Double-blind
P,Double-blind
P,Double-blind
P,Double-blind
P,Double-blind
P,Double-blind
P,Double-blind
P,"Double-blind for all assessments in 12-week therapy phase, Investigators adjusted the number of placebo capsules similarly to maintain the blinding. Single-blind in run-in phase"
P,Double-blind study design
P,Double-blind study design
P,Double-blind study design
P,Double-blind study design
P,Double-blind study design
P,Double-blind study design
P,Double-blind study design
P,Double-blind study design used
Q,"Double-blind study; however, not reported who was blinded and how blinding was obtained."
Q,"Double-blind study. ""double-blind comparison;"" however, not reported who was blinded and how blinding was attempted."
P,"Double-blind study. ""Fondaparinux and placebo were packaged in identical boxes containing visually identical, prefilled 0.5-ml single-dose syringes."" ""All symptomatic outcomes were reviewed by the central adjudication committee, whose members were unaware of the patients’ group assignments."" ""The database of adjudicated outcomes was managed by an independent central adjudication committee."""
Q,"Double-blind study. Authors stated that study was double-blind and placebo-controlled. However, no details regarding study medication or placebo given in main text."
Q,"Double-blind, ""Neither the patient nor the gynaecologist were aware of the gel being applied”"
P,Double-blinded
P,Double-blinded
P,Double-blinded
,Double-blinded trial
,Double-blinded trial
,Double-blinded trial
P,"Double-blinded, “neither the patient nor the attendant physician were aware of the content of the ampoules.”"
,"Double-blinded, placebo-controlled trial"
,"Double-blinded, placebo-controlled trial"
P,"Double-blinded. ""Lidocaine and placebo were packaged in identical bottles and could not be differentiated."""
P,"Double-blinded. ""Participants, attending medical staC and research nurses were blinded to the treatment used."""
P,"Double-blinded. ""Placebo comparable to Essaven gel was used,"" ""operators were unaware of the contents of the tube."""
P,"Double-blinded. ""The patient, research assistant and principal investigator were blinded to the treatment group."""
P,Double-blinding
P,Double-blinding
P,Double-blinding
P,Double-blinding
P,Double-blinding
P,Double-blinding
P,Double-blinding
P,Double-blinding
P,Double-blinding
P,Double-blinding
P,Double-blinding
P,Double-blinding
P,Double-blinding
P,Double-blinding
P,Double-blinding
Q,Double-blinding
Q,Double-blinding
Q,Double-blinding
Q,"Double-blinding, integrity of blinding not assessed (p.220)"
Q,"Double-blinding, integrity of blinding not assessed (p.575, investigator information)"
Q,"Double-blinding, integrity of blinding not assessed, p.438 and investigator information"
Q,"Double-blinding, integrity of blinding not assessed, p.53"
P,Double-dummy method
P,Double-dummy method
P,During recruitment participants were blinded to the focus of the study on alcohol
P,"E-mail from author: ""StaH were blinded to the allocation."" Outcome was influenza Medicare claims."
P,Endoscopies were all performed by the same physician who was unaware of the patient's treatment category
P,Endoscopists were blinded for the treatment
P,"Factorial, double-dummy design; described as double blind; no details of blinding of the observer"
N,Family members not blinded. Not feasible to blind medical staK administering the treatment.
P,Gabapentin 300 mg over-capsulated and identical placebo capsules
P,"General practitioners were blind to allocation, but no information provided on methods of blinding. Person who assessed outcome was blind to the participant group allocation."
Q,"Given the nature of the intervention, it was not possible to blind the participants or the intervention providers. However, the telephone interviewers obtaining follow-up data could have been blinded but the authors do not report 
whether this was done."
P,Groups b) and c) blinded: 'participants remained unaware of their [acupuncture] treatment group assignment'
Q,Handling and blinding of questionnaires not stated
P,Healthcare utilisation measured from automated data.
P,"Healthcare workers caring for participants blinded, participants not blinded"
Q,hose delivering the interventions were aware of treatmentgroup. It is not clear whether this would have introduced bias
Q,hose delivering the interventions were aware of treatmentgroup. It is not clear whether this would have introduced bias
P,"Identical appearance, weight, taste, and smell of tablets for treatments and placebo"
P,Identical blister packs
P,Identical placebo and IVIG prepared separately by pharmacists; syringes and tubing were masked with yellow tape
P,"Identical placebo, persons administering therapy were blinded"
P,"Identically packaged placebo, blinded clinical evaluation committee"
N,"Implied to be an open-label study. Not explicit, but implied open-label with regard to participants and study drug administrators. Detection: ""rater blind"", but no information on how the blinding was maintained."
P,"In follow-ups, telephone interviewers were blinded to intervention; no information provided as to blinding for postal surveys or Medicare claims. However, it is unlikely that contamination could have occurred."
Q,Insufficient description
Q,Insufficient description
P,Investigators were blinded to all outcome determinations; allocation was performed by a biostatistician and was implemented by an epidemiologist
P,"Investigators were blinded to the intervention. Based on this statement and the effective blinding of participants, we judged that the personnel were effectively blinded"
Q,It is unclear whether the SIS for quality of life involved self reports
P,It was attempted to conduct the interviews as a rather open talk on health and social questions; alcohol questions were embedded in other health-related questions (p.1320)
Q,"It was reported that ""The nature of the treatment interventions precluded blinding of patients and treating physicians."" No information on outcome assessment. However, non-blinding of outcome assessors may not have affected some of the outcome measures as they were objectively assessed."
,"It was reported that, ""Dispensation of the topical agent was done by a gynecologist who was not part of the selection/interview team"""
,"It was reported that, ""The first phase was double-blind, randomized, and placebo-controlled"""
P,"IVIG and dextrose were dispensed in similar, unmarked bottles. The physician treating the infants was not aware of the contents. Assessed as non-blind by Pildal and Goetzsche (Pildal 2004); pentaglobin is opaque while dextrose is not; no precautions to conceal this"
P,"Judgement comment: blinding not reported, but unlikely to have affected outcome."
P,Judgement comment: outcomes unlikely to be affected by lack of blinding
,Low risk
N,"Masking was impossible for surgeons It is unclear if patients were aware of their group allocation Outcome assessment was masked ""Postoperatively, wound follow-up was carried out by the infection control nurse who was unaware whether the drape had been used or not"""
N,Masking was impossible for surgeons It is unclear if patients were aware of their group allocation The person assessing the outcome was aware of the patient's allocation group
N,"Masking was impossible for surgeons It is unclear if patients were aware of their group allocation Two of the authors, who were also surgeons involved in the trial, followed up all patients until one month after the surgery to record any wound infection"
N,"Masking was impossible for surgeons It is unclear if patients were aware of their group allocation Whether outcome assessors were masked is unclear. The author states ""After the operation, the wound was observed for clinical infection"" but there was no indication of who undertook this assessment nor if those assessing the outcome were aware of the group allocation"
N,"Masking was impossible for surgeons It is unclear if patients were aware of their group allocation Whether outcome assessors were masked is unclear. The author states ""Postoperative observations of the wounds were continued in hospital until the fourteenth post-operative day"" but there was no indication of who undertook this assessment nor if the assessors were aware of the group allocation"
N,Masking was impossible for surgeons It is unclear if patients were aware of their group allocation Wounds were inspected daily after the third day to identify evidence of infection but it is not clear who did this; nor if the assessors were aware of the patients allocation status
P,"Masking was impossible for surgeons Patients were blind to their allocation as the drape was placed after anaesthetic induction Outcome assessment was blinded, postoperative care was provided by staF unrelated to surgery"
P,Matching placebo
Q,"Measured by self report, but also by completed flu vouchers for payment to physician by Medicare"
Q,Mentions it is 'double blind' but does not explain about blinding regarding participants. Both the nurses and assessing psychiatrists were blind to the dosages of depots given to patients. This 'Blindness' was also tested.
Q,Mentions it is 'double blind'. Assessors were blind to evaluations of other assessors and all previous assessments of their own and also to depot dosages. No information on blinding for personnel or participants or test for blinding.
Q,Mentions it is 'double blind'. Nurse administering the depot was blind to assessments and the assessment team was blind to the drug administered. No explanation of blinding regarding participants. No information on test for blinding.
P,Mentions it is 'double blind'. Rating clinicians and patients were kept ignorant of treatment allocation. No information for test of blinding though.
Q,Mentions that the study was double blind. No other information given.
P,Neither research volunteer nor data gatherers were aware of group assignments'
N,No blinding
,no blinding
,no blinding
,no blinding
,no blinding
,no blinding
,no blinding
,no blinding
,no blinding
,no blinding
,no blinding
,no blinding
,no blinding
N,No blinding
N,No blinding described.
N,No blinding described.
N,No blinding of participants or assessments
N,No blinding of participants or assessors was performed
N,No blinding undertaken.
N,No blinding undertaken.
N,No blinding undertaken.
N,No blinding undertaken.
Q,No blinding was performed because of the nature of the intervention used
Q,No blinding was used during the preparation of injections; in most cases the same person prepared and administered the drug. Study investigators conducting the assessment were blinded to treatment.
Q,"No blinding, information obtained from contact person."
Q,"No blinding, reported primary outcome (QOL) is subjective. However, the other reported outcomes are objective and not likely to be affected by lack of blinding"
N,No blinding.
P,"No blinding. However, the reported outcomes are objective and not likely to be affected by lack of blinding"
P,"No blinding. However, the reported outcomes are objective and not likely to be affected by lack of blinding"
P,"No blinding. However, the reported outcomes are objective and not likely to be affected by lack of blinding"
P,"No blinding. However, the reported outcomes are objective and not likely to be affected by lack of blinding"
P,"No blinding. However, the reported outcomes are objective and not likely to be affected by lack of blinding"
P,"No blinding. However, the reported outcomes are objective and not likely to be affected by lack of blinding"
P,"No blinding. However, the reported outcomes are objective and not likely to be affected by lack of blinding"
Q,"No comment on formulation of drug or placebo but almost certainly double blinded both in up and down titration. However, significantly more participants on duloxetine withdrew with adverse effects"
P,No concerns
Q,No description
Q,"No descriptions, second year of the same study design"
Q,No detail given
Q,No details
Q,No details
,No details reported
N,No details.
N,No details.
N,No details.
N,No details.
N,No details.
N,No details.
N,No evidence of blinding; different dosage schedules make blinding impossible Potential knowledge of treatment may have influenced the primary outcome of MBL which was measured by PBAC
Q,No information
Q,No information about blinding
Q,No information as to whether participants or personnel (or both) were blinded; non-blinding of outcome assessor could have affected the validity of some of the outcomes measured.
Q,No information available about who assessed the respirator fitness
Q,No information provided
N,"No information provided about blinding, but it was likely an open study"
N,"No information provided about blinding, but it was likely an open study."
N,"No information provided about blinding, but it was likely an open study."
N,"No information provided about blinding, but likely an open study"
P,No information provided in published study
Q,No information provided on the blinding of participants and personnel
Q,No information provided.
Q,No information provided.
Q,No information reported but non-blinding of outcome assessors may not have affected some of the outcome measures as they were objectively assessed.
,No information was given with respect to the blinding of participants and/or personnel
,No information was reported on performance bias
P,"No mention was made that the assessment interview was about alcohol consumption, and alcohol questions were embedded amongst other health-related questions"
N,No methods of blinding used
N,No methods of blinding used
N,No methods of blinding used
N,No methods of blinding used
N,No reported attempt to blind participants
N,No reported attempt to blind participants
N,No reported attempt to blind participants
N,No reported attempt to blind participants
N,No reported attempt to blind participants
N,No reported attempt to blind participants.
N,No reported attempt to blind participants.
N,No reported attempt to blind participants.
N,No reported attempt to blind participants.
N,No reported attempt to blind participants.
N,No reported attempt to blind participants.
N,No reported attempt to blind participants.
N,No reported attempt to blind participants.
N,No reported attempt to blind participants.
Q,"No reports on blinding of participants and personnel, although blinding of outcome assessor could not have influenced some of the reported outcome measures"
Q,No specific information given.
Q,No statement
Q,No statement
Q,No statement
Q,No statement
Q,No statement
Q,No statement
Q,No statement
Q,No statement
Q,No statement
Q,No statement
Q,No statement
Q,No statement
Q,No statement
Q,No statement
P,"No statement about blinding, but assessment based on Medicare reimbursement claims"
Q,"No statement about blinding, but vaccinations recorded in clinic computer"
P,"No statement, but chart review by 4 trained personnel using standardised forms, inter-rater reliability = 100%"
P,"No statement, but computerised billing data"
P,"No statement, but influenza vaccination uptake from computerised billing codes, or line listing of vaccinees in practices that were not computerised"
P,"No statement, but influenza vaccinations were recorded by computerised billing system."
P,"No statement, but outcomes ascertained from Medicare Part B claims"
Q,"No statement, but vaccination status assessed by chart review using pilot-tested protocol"
P,"No statement, but vaccination status measured by Medicare billing"
P,"No statement, chart audit for vaccinations (not stated who performed chart audit, but was retrospective), and questionnaires for vaccination received elsewhere"
P,"No statement, however ""outcome data were obtained through telephone interview (or home visit) by two research assistants who were unaware of group membership."""
P,No statement; computerised billing data
P,No statement; outcome data based on billing claims
Q,"No statement: ""Medical records were retrospectively reviewed at the end of the study period to ascertain whether subjects had received influenza vaccine"""
P,No subjective outcomes were included in this study
P,No subjective outcomes were included in this study
P,No subjective outcomes were included in this study
P,No subjective outcomes were included in this study
P,No subjective outcomes were included in this study
P,No subjective outcomes were included in this study
P,No subjective outcomes were included in this study
P,No subjective outcomes were included in this study
Q,"None of the participants, clinicians or assessors appeared to have been blinded. However, some of the outcomes reported were derived from hospital and school records and so less likely to be prone to bias from a lack of blinding; other outcomes measured via questionnaire were however prone to bias"
Q,"None of the participants, clinicians or assessors appeared to have been blinded. However, some of the outcomes reported were derived from medical chart reviews and so less likely to be prone to bias from a lack of blinding; other outcomes measured via questionnaire were however prone to bias"
N,"None of the participants, clinicians or assessors appeared to have been blinded. The subjective nature of the outcomes measured (all by self reported questionnaire) means this may have introduced bias"
N,"None of the participants, clinicians or assessors appeared to have been blinded. The subjective nature of the outcomes measured (all by self-reported questionnaire) means this may have introduced bias"
Q,Not applicable
Q,Not applicable
Q,Not applicable
Q,Not applicable
Q,Not applicable
Q,Not applicable
Q,Not applicable
Q,Not applicable
N,Not blinded
N,Not blinded
N,Not blinded
N,Not blinded
N,Not blinded
N,Not blinded
N,Not blinded
N,Not blinded
N,Not blinded
N,Not blinded
N,Not blinded
N,Not blinded
N,Not blinded
N,Not blinded
,not blinded
,not blinded
,not blinded
,not blinded
,not blinded
,not blinded
,not blinded
,not blinded
,not blinded
,not blinded
,not blinded
N,Not blinded
N,Not blinded; no reported attempt to reduce bias.
N,Not blinded; no reported attempt to reduce bias.
N,Not blinded; no reported attempt to reduce bias.
N,Not blinded; no reported attempt to reduce bias.
N,Not blinded.
N,Not blinded.
N,Not blinded.
N,Not blinded.
N,Not blinded.
N,Not blinded.
N,Not blinded.
N,Not blinded. Completed AUDIT for screening therefore alcohol focus clear
N,Not blinded. Screened by AUDIT.
N,Not blinded. Screening tools alcohol focused.
Q,Not described
Q,Not described
Q,Not described
Q,Not described
Q,Not described
Q,Not described
Q,Not described
Q,Not described
Q,Not described
P,Not described
Q,Not described
Q,Not described
Q,Not described
Q,Not described
N,"Not described, but research interviewers collected some data from medical records, therefore unlikely to be blinded."
Q,"Not described, raters 'independent of treatment teams'."
Q,Not described.
Q,Not described.
Q,Not described.
Q,Not described.
Q,Not mentioned
Q,Not mentioned in the paper
N,Not possible
N,Not possible
N,Not possible
N,Not possible
N,Not possible due to nature of intervention and outcomes collected by research due to limited resources
N,Not possible for this intervention
P,Not possible to blind clinicians and participants but cluster design. Outcome assessors blinded
Q,Not possible to blind participants and clinicians due to nature of intervention. Outcome assessors: data collected from care plans
N,Not possible to blind participants or personnel (supervisors) to treatment allocation
N,Not possible to blind participants or personnel (supervisors) to treatment allocation
N,Not possible to blind participants or personnel (supervisors) to treatment allocation
N,Not possible to blind participants or personnel (supervisors) to treatment allocation
N,Not possible to blind participants or personnel (supervisors) to treatment allocation
N,Not possible to blind staK who had to apply either CPAP or intubation.
N,Not possible to blind staK who had to apply either CPAP or intubation. Data were collected on infants during intervention phase so not possible to blind outcome assessors for primary outcome
N,Not possible to blind staK who had to apply either CPAP or intubation. Not possible to blind outcome assessors for primary outcome
Q,Not possible with this design
Q,Not reported
Q,Not reported
P,Not reported
P,Not reported
P,Not reported
Q,Not reported
Q,Not reported
,Not reported
,Not reported
Q,Not reported but non-blinding of outcome assessors may not have affected some of the outcome measures as they were objectively assessed
Q,Not reported but non-blinding of outcome assessors may not have affected some of the outcome measures as they were objectively assessed.
Q,Not reported but non-blinding of outcome assessors may not have affected some of the outcome measures as they were objectively assessed.
,Not reported but participants were likely to be unblinded since the 2 treatments required different administration
Q,Not reported but primary outcomes automated
Q,Not reported whether participants or personnel (or both) were blinded
Q,Not reported whether participants or personnel (or both) were blinded; nonblinding of outcome assessors could have influenced some of the outcome measures.
Q,Not reported.
Q,Not reported.
Q,Not reported.
Q,Not reported.
Q,Not reported.
Q,Not reported.
Q,Not reported.
Q,Not reported.
Q,Not reported.
Q,Not reported.
Q,Not reported. Outcome data collected by 'study staE'
Q,Not stated
Q,Not stated
Q,Not stated
Q,Not stated in text
Q,Not stated whether the reviewers were blinded
Q,Not used
Q,Not used
,NR.
P,"Numbered, identical-looking syringes"
Q,Only doctors who retrieved oocytes and embryologists were blinded to treatment groups.
N,Only participants who had received 4 previous doses of DTwP were blinded to which vaccine they received for the fiQh dose
N,Open design
,Open label (no blinding)
,Open label (no blinding)
,Open label (no blinding)
,Open label trial
,Open label trial
,Open label trial
,Open label trial
N,Open study
N,open study
N,"Open study ""open and multicenter."""
N,"Open study, no description of observer blinding"
N,"Open study, though the observers were blinded"
N,Open study.
N,Open study.
N,"Open study. ""open tria"
N,Open-label
N,Open-label
Q,Open-label RCT but non-blinding of outcome assessors may not have affected some of the outcome measures as they were objectively assessed.
N,Open-label study with assessment by blinded clinical raters
N,"Open-label study with blinded outcome assessment. Quote: ""An independent committee, whose members were unaware of study group assignment, adjudicated the qualifying diagnosis, the anatomical extent of the initial superficial-vein thrombosis, and all suspected outcomes."""
N,Open-label study.
N,Open-label study.
N,Open-label study. No evidence for any rater blinding- follow-up methods differed between treatment groups (phone calls for quetiapine group and in person with depot risperidone).
N,Open-label study. No evidence of rater blinding.
N,"Open-label, participants and study drug administrators were not blinded, but with blinded raters."
N,"Open-label. Rater blinding: ""all efficacy assessments were administered and evaluated by independent, blinded and trained raters at each site."""
N,Outcome assessment of behaviours was done by the participants themselves and thereby introduced a possible bias
P,Outcome assessor blinded.
Q,Outcome assessor blinded. Blinding of participant and care provider not described.
Q,Outcome assessor blinded. Blinding of participant and care provider not described.
Q,Outcome assessor blinded. Study authors did not indicate if participant and care provider were blinded.
Q,Outcome assessor blinded. Study authors did not indicate if participant and care provider were blinded.
P,Outcome assessor was blinded
P,Outcome assessor was blinded
P,Outcome assessor was blinded
P,Outcome assessor was blinded to treatment conditions
N,Outcome assessor was blinded. Participant and care provider were not blinded.
N,Outcome assessor was blinded. Participant and care provider were not blinded.
Q,Outcome assessors and statistician blinded; not possible to blind professionals and participants due to nature of intervention
P,Outcome assessors blinded
P,Outcome assessors blinded
P,Outcome assessors were blinded
P,Outcomes assessed by a death review committee and a study pathologist who were unaware of study allocation
P,Outcomes collected in symptom diaries not seen by the investigators.
P,Outcomes were determined blind
P,Outcomes were obtained from or confirmed by public registries. A second analysis as CRCas an underlying cause of death was obtained after blinded verification of death certificates by an independent expert coder who had access to clinical information when available
P,Outcomes were obtained from public registries
P,Outcomes were obtained from public registries by a person not involved in the trial
Q,Parents and nurses collecting efficacy and adverse event data were blinded but blinding details not stated
P,"Participant and doctor blinded, but there was no description of outcome assessor blinding."
P,"Participant and doctor blinded, but there was no description of outcome assessor blinding."
P,Participant blinded
P,Participant blinded. 'Treatment was administered by a single clinician blinded ... to ... treatment'
N,Participants and clinicians were not blinded; it is unclear if the trained interviewers were blinded. The subjective nature of the outcomes measured (by self-reported questionnaire) means this may have introduced bias
N,Participants and clinicians were not blinded; it is unclear if the trained interviewers were blinded. The subjective nature of the outcomes measured (by self-reported questionnaire) means this may have introduced bias.
N,Participants and study staG were not blind to the intervention allocation
N,Participants and study staG were not blinded to allocation.
N,Participants and study staG were not blinded to the intervention
N,Participants and study staG were not blinded to the intervention
N,Participants and therapists not blinded: assessor blinding unclear
N,Participants and therapists were not blinded because of 2 different therapiesappliedComments: not reported if the others involved in the research were blinded
P,"Participants blinded and doctor blinded, outcome assessor/pathologist unclear, review/coding of medical records unblinded"
P,Participants blinded throughout the 2-year follow-up (unpublished information)
P,Participants blindfolded; independent observer not involved in the treatment
Q,Participants did not know treatment type they were receiving. The outcome of treatment was not determined blind
Q,"Participants filled in a healthy lifestyle questionnaire as well as alcohol questions at screening, but all participants received an alcohol-related educational brochure (p. 132)"
Q,Participants in groups A and B were not blinded to the allocation; participants in group C were unaware of study participation. It is not reported whether study staG were blinded to the interventions.
,participants knew if they were in the control or intervention group (type of earplug and training)
N,Participants not blinded (p. 632).
Q,Participants not blinded. No report of blinding observer
,Participants were blinded but unclear whether the clinicians were blinded
P,"Participants were blinded to group allocation, as were the monitoring and research staA"
Q,Participants were not blinded to intervention; it was not reported if study or medical staG were blinded to the intervention
P,Participants were not blinded to the intervention; data collectors were blinded.
N,Participants were not blinded to the intervention. Blinding of study staG and physicians was not reported.
Q,Participants were not blinded to the intervention. It was not reported if study or medical staG were blinded to the intervention
Q,Participants were not blinded to the intervention. It was not reported if study or medical staG were blinded to the intervention.
N,"Participants were not blinded, screening questions concern alcohol consumption (National Institute on Alcohol Abuse and Alcoholism quantity and frequency questions and the CAGE questionnaire)"
P,Participants were not blinded; clinic staG were unaware of treatment allocation.
P,Participants were not blinded.
P,"Participants, investigators and assessors blinded"
P,"Participants, investigators and assessors were all blinded"
P,"Patient and care provider were blinded, but unsure regarding outcome assessor."
P,"Patient and care provider were blinded, but unsure regarding outcome assessor."
P,Patients completed a modified Health Screening Survey with alcohol questions embedded
N,Patients knew that alcohol advice was being evaluated (p. 429)
N,Patients were screened with a general health questionnaire but were told that the study was about the way people’s drinking changes over time (p. 359)
N,"Physicians in the Department of Family Practice were aware that a study was in progress and that some of their patients might receive postcards about influenza immunisation. Vaccine was offered to all eligible participants on a walk-in basis. Participants who presented for immunisation read and signed an informed consent document. It is not stated if the physicians were those who performed the vaccinations. However, participants might have told their vaccinator whether or not they had received a postcard."
Q,"Placebo ""matched for shape, size, colour and taste"""
Q,"Placebo ""matched for shape, size, colour and taste"""
Q,"Placebo tablets and injections used to blind participants. ""Double blind"" stated but it is not clearly expressed who exactly was blinded, cannot be sure if rater blinded."
P,Placebo-controlled
P,Placebo-controlled
P,Placebo-controlled
P,Placebo-controlled
P,Placebo-controlled
P,Placebo-controlled
P,Placebo-controlled (human serum albumin)
P,"Placebo-controlled (human serum albumin), blinded clinical evaluation committee"
P,"Placebo-controlled, blinded clinical evaluation committee"
P,"Placebo-controlled, identical in appearance"
P,"Placebo-controlled, identical vials"
P,"Placebo-controlled, independent safety and efficacy monitoring committee"
P,Placebo-controlled; all participating individuals except the pharmacist and statistician were blinded to the treatment patients received
P,Placebo-controlled; independent safety and efficacy committee
P,Placebo-controlled; independent safety and efficacy monitoring committee
P,"Postal questionnaires and ""analyst blind to practice allocation to trial arms"""
Q,Probably double-blinded but no additional details reported on outcome assessor
Q,"Probably double-blinded, but no details reported on outcome assessor; reported that ""antibiotic...labeled only with patient's name""; unclear whether this will affect blinding"
P,"Quote (from the author): ""Patients were blinded to the group assignment. We also did not include any patients who had previous acupuncture so they would not know if it was actual or sham acupuncture. We did not blind the investigators"""
P,"Quote (from the report): ""To minimize the potential confounding effect of the acupuncturist’s awareness of which treatment participants were receiving, acupuncturists were trained to maintain a standardized interaction with all participants. All sessions were audio-taped, of which five percent were randomly selected and reviewed for adherence to the standardized protocol by an independent rater who remained blind to the type of treatment received"" Quote (from the author): ""Placebo treatment included none acupuncture points but to the inexperienced patient these are very similar (proximal) to actual points and similar in number to the treatment group. The acupuncturists were instructed on how to verbally conduct the session, to avoid any conversation other than the pre determined protocol. This included length of the session and wording. Investigators were not aware of the allocation of the patients to treatment or placebo group during the study when meeting with the patients in the first session as well as when reviewing hot flash log data"""
N,"Quote of author: ""So, the patients knew which treatment (pills of HT or acupuncture) they were getting. All women, no matter if they were offered HT or acupuncture, chose to start the treatment they were randomized to"""
P,"Quote: ""All analyses were conducted blind to group allocation”""[The participants] were not told which treatment they would received. In ad-dition, to eliminate observation bias, the two assessors were blind to the inter-vention group before analysis of data"""
Q,"Quote: ""All participants and investigators were masked to treatment assignment and also blind to the size of each block."" Comment: reported as a double-blind study; however, not stated that the 2 dosages of study drug had identical appearance."
N,"Quote: ""All researchers remained blinded throughout the study. A person blinded to group allocation entered data on hot flashes and sleep into the database. The randomization code was broken only after the analyses of the primary outcomes were completed"" ""Participants were not blinded because they had acupuncture or a one page information of self-care menopausal symptoms"""
Q,"Quote: ""Although the patient could guess her treatment status, treatment allocation was not recorded in the clinical notes, and all clinicians were blinded to the status of study participants until the trial was over."" However, no information on outcome assessors."
N,"Quote: ""As with any therapy trial, participants, therapists, and doctors could not be masked to treatment allocation and it was also impractical to mask research assessors. The primary outcomes were rated by participants themselves"""
N,"Quote: ""Because 20% mannitol can crystallize at ambient temperature, injections could not be performed in a blinded manner."""
P,"Quote: ""Group acupuncture and sham-acupuncture were both patient - and in-vestigator blinded""""Participants of no treatment group were not blinded"""
N,"Quote: ""no patient or investigator was blinded to the patient's status after assignment to a study group"", ""administering a placebo and blinding patients to their group assignment would have been impracticable because the physiologic effects of propranolol are distinctive and difficult to mask or to mimic with placebo"" Comment: this study was an open-label study and both participants and investigators were aware of study group they were assigned."
P,"Quote: ""open-label"" but the primary outcome (residual kidney function) was not likely to be influenced by the status of blinding"
P,"Quote: ""open-label"" but the primary outcome (residual kidney function) was not likely to be influenced by the status of blinding"
P,"Quote: ""open-label"" but the primary outcome (residual kidney function) was not likely to be influenced by the status of blinding"
P,"Quote: ""Patients and physicians giving the interventions were aware of assignment.""Judgement comment: not blinded but unlikely to be affected."
P,"Quote: ""Patients were blinded to the type of acupuncture received. All participants were in a separate room with an eye bandage and no-patient-practitioner communication was allowed"" ""All data was collected by a blinded assessor"""
P,"Quote: ""Patients were blinded to the type of acupuncture received"" ""A neutral attitude towards the patients and potential treatment effects was attempted, and all data was handled by a secretary blinded to the treatment group"""
P,"Quote: ""Study retention was excellent with all women remaining in the study. However, not all women completed all study procedures. Eight (42%) of the women in the TA group and 10 (56%) in the SA group completed at least (80%) of the 16 treatments. Furthermore, two women in the UC group did not complete any follow-up diaries, one in the SA group, and three in the TA group"" Nothing reported about reasons for treatment withdrawal/not completing all study procedures Analyses were conducted with an ITT approach Nothing mentioned about imputation method"
N,"Quote: ""The drug treatment was double blind. The placebo to fluoxetine was a capsule of similar taste and appearance. The placebo to the exercise programme was a review of activity diaries by the physiotherapists"""
N,"Quote: ""The evaluator and the research therapists were not blinded because they were involved in the processes of assessment and intervention ..."""
P,"Quote: ""The gynaecologists and nurses evaluating the patients were blind to treatments, i.e. at evaluation, the physician and research nurse did not know which acupuncture treatment each women had and not until after analysis of the results did we unveil the treatment modalities. Furthermore, the patients were only informed that two different modalities were used but not that we expected one to be more efficient"""
Q,"Quote: ""The laboratory staL were blinded to the stimulation protocol."" Unclear if treating physicians were blinded."
,"Quote: ""There was no blinding"""
P,"Quote: ""This study was designed as a single-blind, randomised, controlled clinical trial"" ""During the final visit study subjects were asked to guess whether they had received placebo or real acupuncture, and at what stage they came to that conclusion. This helped us assess how successful our blinding was"" Comments: participants blinding only"
N,"Quote: ""This study was not blind."""
N,"Quote: ""This was an open trial, so patient blinding was unavailable. We failed to blind the assessor to assignment of patient. Instead, all outcomes were selfadministered by patients, and the researcher who was separated from the treatment procedure collected the data. Data were sent to the central research centre, and personal who were independent of this study entered the data"""
P,"Quote: ""Treating physicians and OT evaluator were unaware of the patient’s study group assignment. Patients were instructed to avoid discussing their exercise assignment with either the OT evaluator or their physician and to contact one of the investigators with questions or problems."""
N,"Quote: “It was not possible to mask participants and therapists to treatment allocation."""
,"Quote: “open-label, multicentre randomised controlled trial was conducted”. Comment: open label RCT, so blinding of healthcare providers not done."
,Quote: “Preparation and application of dressings were performed by qualified nurses unaware of the study protocol”. Comment: This implies they could see what the dressings were but were unaware of the detail of the study therefore the potential for performance bias is there.
,Quote: “Removal and application of all dressings were performed in a treatment group with only the investigator and participant present”. Comment: blinding of healthcare providers not done.
,Quote: “The assessor was not aware of the treatment given (single blind)”. Comment: blinding of providers was not done.
,"Quote: “The study was designed as a single centre, open-label, randomized controlled trial”. Comment: open label RCT, so blinding of healthcare providers not done."
,Quote: “The study was single blind trial. While the operating clinician and the patients could not be blinded to the intervention . . .”. Comment: blinding of healthcare providers not done.
Q,"Randomisation was blinded for the GPs. However, GPs were paid the equivalent of USD 36 for each patient vaccinated without patient fee."
N,Rated as 5 on 'Risk of bias' scale as no blinding techniques used in study
N,Rated as 5 on 'Risk of bias' scale as no methods of blinding were employed
N,Rated as 5 on RoB scale as no methods of blinding were used.
N,Rated as 5 on RoB scale as no one was blinded in this study.
Blinding of intervention,REASON-Blinding of intervention
Blinding of intervention,REASON-Blinding of intervention
P,Recruitment letter to participants does not discuss alcohol as a reason for attendance but just that elevated blood test needed a follow-up
,"Reported as ..""double-blind, randomized, placebo-controlled, clinical trial.."""
P,"Reported that ""none of the investigators knew if the patient had got metronidazole or placebo"""
P,"Reported that ""the code was not broken until the patient had been discharged and evaluated..."""
Q,"Reported that intervention providers were blinded to endometrial preparation; however, participants and outcome assessors were not blinded. Nonblinding of outcome assessors could affect some of the outcome measures"
Q,"Reported that study was a non-blinded open trial and this could have affected the validity of the entire processes leading to outcome measures; however, non-blinding may not have affected some of the outcome measures as they were objectively assessed."
N,Researchers collecting measures not blinded.
Q,Says it is double blind study. Blinding of participants explained but not for personnel and outcome assessors.
Q,"Says it is double blind. 'Same injection interval and dose kept constant', no other information."
Q,Says it is double blind. Injections were given by a nurse who did not participate in assessments. Blinding of participants not explained. No information on test of blinding.
Q,Says trial is double blind. No other information given.
P,Screening and baseline questionnaires were broad and not focused on alcohol (p. 1445)
P,Screening questionnaire had filler questions to mask recruitment criteria (p. 57)
N,Screening was by alcohol tools; control group received a leaflet specifically about drinking
N,"Screening, baseline an follow-up questionnaires were not masked (p. 365)"
P,See Atkin 2010
P,See Ho$ 2009
P,See Kronborg 2004
P,See Kronborg 2004
P,See Linndholm 2008
P,See Mandel 1993
P,See Mandel 1993
P,See Scholefield 2002
P,See Segnan 2011
P,See Thiis-Evensen 1999
N,Self report measures were used for subjective outcomes
N,Self report measures were used for subjective outcomes
N,Self-reported behaviours
P,Sham or inactive probe
Q,Single
P,Single
Q,Single blind study - assessment was conducted by physicians who were unaware of treatment condition
N,"Single blind: ""observer blinded design."""
N,"Single blinded. ""The patients were blinded but the operators were aware of the content of the solution."""
P,Single blinding (participants were blinded by covering the points with flexible dressing)
Q,Single-blind study - assessment was conducted by physicians who were unaware of treatment condition
P,Single-blind study design
P,Single-blind study design
N,Single-blinded - outcome assessor blinded
N,Single-blinded - women were blinded to the assignment because they were not told how many injections each group would be receiving
Q,Single-blinding
Q,"Single, but not tested"
Q,Some of the personnel were blinded (pre-ET US examination); no information on blinding of either participants or outcome assessor and non-binding of outcome assessor could influence some of the outcome measures
,Stated as “double blind”
Q,Stated that contents of envelopes were known only to medical staG who were not involved with the trial. Not reported whether the outcome assessor was blinded; however non-blinding was likely to influence some of the outcome measures
Q,"States ""in the double-blind mode"" - no additional details"
Q,"States ""the co-trimoxazole and placebo were supplied in ampoules containing 3 mls fluid...the placebo ampoule contained saline solution""; no information on outcome assessor"
Q,"States ""the placebo was a...material...with the identical appearance of the active drug""; no information on outcome assessor"
P,"States ""vial and colour of the solution being indistinguishable...the observer was unaware of the antibiotics used..."""
Q,"States as blinded for participants, but not clear if blinded for practitioners; no information on outcome assessor"
Q,States design was double blind. No other information given. No test for blinding.
Q,States it is a double-blind comparative trial. No other information given.
Q,States it is double blind study. No other information given.
Q,"States that ""a double-blind clinical evaluation was performed."" No information on outcome assessor reported"
Q,"States that ""ampoules of apparently identical fluid..."" were administered; no additional details on outcome assessor were reported"
P,"States that ""participants, their physicians and all investigators were blind to the allocation throughout the study"""
P,"States that ""patients and investigators were blind to the allocation throughout the study"""
P,"States that ""the code identifying placebo or active drug was broken only after the patient had been discharged and the clinical summary sheets...completed"""
Q,"States that ""the placebo group received the placebo with the saline in the same manner""; no details reported on outcome assessor or evaluation of participants"
P,"States that ""the study was so designed that the medical and nursing personnel would not be aware of the group allocation of the patients studied"""
P,"States that ""the study was so designed that the medical and nursing personnel would not be aware of the group allocation of the patients studied"""
Q,States that conduct of study was as described in Mathews 1977 (see above)
N,States that study was unblinded; the investigators presented the intervention to the participants
P,Study drug administrator was the only person to contact IVRS to receive medication number and was not allowed to communicate patient-related information to study site personal or to perform any efficacy and safety assessment. Patient and staC performing study-related procedures were to be precluded from seeing the contents of syringe or observing the injection.
P,Study investigators were blinded to computer algorithm group A vs group B allocation; statisticians were blinded to allocation.
P,Study investigators who assessed cause of death and pathologists were unaware of group allocation
P,Study investigators who assessed cause of death and pathologists were unaware of group allocation
N,"Study is described as non-blinded in the title, however in the discussion comments that ""the main limitation of our study was that it was not double-blinded, as we were unable to prepare a placebo with identical appearance and texture to the EMLA gel in our laboratory."" This suggests that the operator would not be blinded, the participant may have been."
P,"study not described as blinded, but clearly designed subject-blinded"
P,"study not described as blinded, but clearly designed subject-blinded"
N,"Study participants were not blinded, but outcome assessors were blinded."
N,"Study participants were not blinded, but outcome assessors were blinded."
N,Study reported as open label.
,"Study was described as, ""randomized, doubleblind, placebo-controlled study."""
,"Study was reported as ""'double-blind, randomized, parallel-group, placebo controlled, multicenter trial"""
P,Subjective outcomes were not used in this study
P,Subjective outcomes were not used in this study
P,"Subjects randomised into the control condition “were told that the trial focused on health behaviours, which included questions on smoking, exercise, eating behaviour, weight and alcohol use” (p. 265)"
P,"The assessors of qualitative fit testing were blinded to the group (i.e. A, B or C) of the participant tested"
P,"The attending surgeon, assistants and patients were unaware of the content of the solution, which had been prepared by an operating room nurse"
N,The authors were not blinded to the allocated interventions
N,The authors were not blinded to the allocated interventions
N,The authors were not blinded to the allocated interventions
P,The duloxetine and placebo capsules were identical in appearance to maintain the blinding. Participants and investigators were kept blinded to the rescue criteria and dose increase; site personnel entered the major depressive disorder status at baseline and the CGI-I for Depression scores through IVRS at every visit
P,the endoscopists were blinded to the treatment type and any clinical information related to the patients
P,The hysteroscopist and woman were blinded
P,The independent investigators who assessed outcomes were blinded to group allocation
N,"The investigators assessing outcomes and statistician were blinded to the treatment assignment. Placebo was not used, so women and clinician who performed the intervention knew pre-medicated women"
P,The investigators were unaware of the trial allocation during the assessment of death certificates
P,"The participants were blinded as to the randomization status, the waiting list control group necessarily knew their randomization status. Both TA and SA groups were required to wear eye covers throughout the treatment The treating acupuncturists were unblinded, to know whether to deliver TA or SA Comments: nothing mentioned concerning the blinding of the outcome assessors"
N,The self-completed questionnaire introduced a possible bias
N,The study was open-label
P,The trained interviewers who assessed occupational respiratory symptoms were blinded to the interventions
P,The trained observers were blinded to the participants’ group assignment
P,The treating physicians were blinded to the randomisation status
P,The treating physicians were blinded to the randomisation status
P,"The trial maintained blinding by using over-encapsulated duloxetine and pregabalin capsules, matching placebo and an identical dosing regimen for all groups in terms of numbers and timing of capsules"
N,The trial was not blinded to participants and study staG
N,The trial was open-label to participants and study staG
N,There was no blinding
Q,This information was not available
N,"This study was described as an open randomised trial, so no blinding was used."
N,"This study was described as an open randomised trial, so no blinding was used."
Q,This was not mentioned
Q,This was not mentioned
Q,This was not mentioned
Q,This was not mentioned
Q,Those delivering the intervention were not blinded; the effect of this on bias is unclear
Q,Those personnel delivering exercise were aware of group alloca-tion. It is unclear whether this introduced bias
Q,Those personnel delivering exercise were aware of group alloca-tion. It is unclear whether this introduced bias
P,"to maintain blinding, the active and placebo tablets were identical in terms of appearance, taste and smell, as well as packaging and labelling"
N,Treating physician not blinded as this was the person to allocate the participants.
N,Treatment and control groups were given their pills on different days of the menstrual cycle
,"Trial was a ""double-blind, placebo-controlled, parallel-group 12-week study"""
P,"Trial was blind to patient, nurse and doctor. No information on test of blinding though."
Q,"Ultrasound assessment performed by blinded investigators. However, not reported if participants and investigators evaluating all other events were blind to study treatment."
N,"Unable to blind participants, due to different regimens It is unclear whether or not personnel were blinded Potential knowledge of treatment may have influenced the primary outcome of MBL which was measured by PBAC"
N,Unblinded.
Q,Unclear description of blinding methods
Q,Unclear description of blinding methods
Q,"Unclear for primary outcome, reported as done for secondary outcomes"
Q,Unclear if outcome assessor blinded
Q,Unclear; participants only blinded
P,Vaccine and placebo syringes were identical in appearance except for the allocation numbers.
P,"Volunteers who responded to an invitation through mass-mailing were randomised using a central block-randomisation process stratified according to screening centre, age and gender"
Q,Women were aware of group
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
